Chronic Obstructive Pulmonary Disease (COPD)
Best Practices in Managing Patients with Chronic Obstructive Pulmonary Disease (COPD)
Chronic Obstructive Pulmonary Disease (COPD) is a preventable and treatable disease which is characterized by chronic airflow limitation and a range of pathological changes in the lung, significant extra-pulmonary effects, and important comorbidities which may contribute to the severity of the disease in individual patients. COPD refers to a disease that causes airflow blockage and breathing-related problems including emphysema, chronic bronchitis, or both1.
AMGA partnered with Boehringer Ingelheim Pharmaceuticals, Inc. to develop the Best Practices in Managing Patients with Chronic Obstructive Pulmonary Disease Compendium. The Compendium includes case studies from medical groups, independent practice associations, academic practices, and integrated delivery systems that have incorporated the management of chronic obstructive pulmonary disease (COPD) into their chronic care models.
The case studies outline the particular interventions and how they worked to make progress towards the following common goals:
Early identification and diagnosis of patients at risk for or currently suffering with symptoms of COPD
Improved medication adherence and compliance
Continuity of care across settings and transitions of care
Increased ability to self-manage symptoms and disease progression through healthier lifestyles
Improved health and well-being, and patient satisfaction
Improved physician/patient relationships
The featured groups participated in the 2010-2011 and the 2012-2013 Best Practices in Managing COPD Learning Collaboratives.
The Best Practices Learning Collaborative is for organizations that are striving to improve the care of patients with COPD. Participating project teams will be able to regularly network with peers, participate in bi-monthly conference calls on relevant project topics, attend two in-person meetings, and have timely access to industry experts. Through a yearlong series of activities, participating organizations had the opportunity to test approaches and design care processes that are relevant to their clinical and operational models.
Ten medical groups have been awarded $7,500 grants to support their initiatives. The learning collaborative commenced in July 2012 and concluded in July 2013.
If you have questions or need further information, contact Danielle Casanova at (703) 838-0033, ext. 347.
1 Global Initiative for Chronic Obstructive Lung Disease Executive Committee. Global strategy for the diagnosis, managements, and prevention of chronic obstructive pulmonary disease. Medical Communications Resources, Inc; 2009.
The featured medical groups were selected solely by AMGF without input from BIPI. Selection as a participating medical group does not constitute an endorsement or referral by Boehringer-Ingelheim Pharmaceuticals, Inc., its affiliated companies, its board of directors or its employees (collectively, "BIPI"). The program was sponsored by BIPI, however the content and opinions expressed herein were selected, developed and written by or with the oversight of AMGF, and do not necessarily reflect the opinions of BIPI.